Scarica l'app Stockscreener
516.56
0.65%
3.35
Dopo l'orario di chiusura:
516.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs - Moomoo
MDGL Reinstated by Goldman Sachs -- Price Target Announced at $7 - gurufocus.com
Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
Goldman Sachs Reinitiates Coverage on Madrigal Pharmaceuticals (MDGL) with Buy Rating and $704 Price Target - gurufocus.com
Madrigal Pharmaceuticals Inc (YDO1.DU) valuation measures and financial statistics - Yahoo Finance Australia
MDGL Initiates Coverage On Citigroup -- Price Target Announced a - gurufocus.com
Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725 - Moomoo
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target - Yahoo Finance
Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high - AD HOC NEWS
(MDGL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Madrigal Pharmaceuticals stock trades around 531 dollars as institutional interest stays strong - AD HOC NEWS
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook on a Biotech Powerhouse with 27.57% Potential Upside - DirectorsTalk Interviews
Madrigal Pharmaceuticals Inc (YDO1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Madrigal Pharmaceuticals stock holds above 530 dollars after recent ownership change - AD HOC NEWS
Madrigal Pharmaceuticals stock holds near $531 after fresh analyst data - AD HOC NEWS
How New Headquarters At Madrigal Pharmaceuticals Stock Has Changed Its Investment Story - simplywall.st
Madrigal Pharmaceuticals Inc (YDO1) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - simplywall.st
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - Stock Titan
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - Stock Titan
September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq
Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - The Manila Times
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Madrigal Pharmaceuticals (MDGL) Declines 1.83% to $533.76 as Consolidation ContinuesShort Setup Alerts - careplusvn.com
Madrigal Grants Stock Awards to 13 New Employees - MyChesCo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - Stock Titan
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - Stock Titan
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):